沙眼衣原体培养、活力检测与测序方法的叙述性综述
过去十年培养技术进展有限,活力评估与耐药检测方法虽有前景但缺乏标准化和广泛实施,表型药敏仅限专业实验室,验证的基因型检测不易获得。
要点
- 沙眼衣原体培养在菌株分型、治愈试验、性侵调查和耐药监测中仍有价值。
- 过去十年培养技术进展有限,活力检测与耐药检测方法缺乏标准化。
- 表型药敏仅限专业实验室,验证的基因型耐药检测不易获得。
核心结论
- 沙眼衣原体培养在常规临床实践中需求下降,但在研究、监测和特定临床场景中仍有作用。
- 当前技术显著缺口包括无法区分活菌与非活菌,以及缺乏标准化药敏方案和基因型耐药检测。
主要发现
- 过去十年沙眼衣原体培养技术进展有限。
- 多种方法在活力评估和耐药检测方面显示前景,但标准化和广泛实施仍缺乏。
- 表型药敏仅限专业实验室,验证的基因型检测不易获得。
临床怎么用
- 沙眼衣原体培养可用于菌株分型、治愈试验、性侵调查和耐药监测。
- 常规临床中沙眼衣原体培养需求下降,但研究、监测和特定场景仍需培养。
局限性
- 无法区分活菌与非活菌。
- 缺乏标准化药敏方案和基因型耐药检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chlamydia trachomatis (CT) is the most commonly reported bacterial sexually transmitted infection in the United States and is routinely detected using nucleic acid amplification tests (NAATs). However, its obligate intracellular life cycle creates challenges for culture, viability determination, and antimicrobial susceptibility testing (AST). Despite these challenges, culture remains important for select applications, including strain typing, test-of-cure, sexual assault investigations, and resistance monitoring. METHODS: We conducted a systematic literature search across 5 electronic databases using defined terms to identify studies on CT culture methods, viability assays, and molecular or phenotypic approaches for antimicrobial resistance detection. Twenty-nine manuscripts met inclusion criteria and were synthesized narratively. RESULTS: Our review found limited progress in CT culture techniques over the past decade. While several methods show promise for viability assessment and resistance detection, standardization and widespread implementation remain lacking. Phenotypic AST is restricted to specialized laboratories, and validated genotypic assays are not widely available. These gaps hinder accurate assessment of treatment failure and resistance trends. CONCLUSIONS: The need for CT culture in routine clinical practice is declining, but culture continues to play a role in research, surveillance, and select clinical scenarios. Significant gaps in current technology include the inability to distinguish viable from nonviable organisms and lack of standardized AST protocols and genotypic resistance assays. Future research should prioritize development of clinical viability assays, consensus AST methods, and integrated genomic approaches to improve diagnostics and strengthen surveillance.
引用
- Sterkel AK, Loya TJ, Smith AC, et al. Narrative Review of Chlamydia trachomatis Culture, Viability Testing, and Sequencing Methods. Clin Infect Dis. 2026. PMID: 41733544. doi:10.1093/cid/ciaf697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。